skip to Main Content
oral medicine in hand

QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS

QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced that the company recently initiated dosing in a Phase 1 clinical trial of QRL-101 (QRA-244), a first-in-class selective Kv7.2/7.3 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS.
doctor smiling

QurAlis Receives Health Canada Trial Application Authorization

QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced the authorization of its clinical trial application (CTA) by Health Canada for QRL-201, a first-in-class STATHMIN-2 (STMN2) precision medicine for ALS.
Back To Top